alexa Cardiac Effects of Glucagon-Like Peptide 1 with Chitosan-Based Scaffold after Inducing Myocardial Infarction in Dogs | OMICS International| Abstract
ISSN: 2329-6607

Cardiovascular Pharmacology: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Cardiol Pharmacol 2015, Vol 4(4): 159
  • DOI: 10.4172/2329-6607.1000159

Cardiac Effects of Glucagon-Like Peptide 1 with Chitosan-Based Scaffold after Inducing Myocardial Infarction in Dogs

Sam Zeraatian1, Abbas Salehiomran2, Ruhollah Mehdinavaz Aghdam2, Seyed Hossein Ahmadi Tafti1*, Seyed Reza Ghiasi3, Nasim Kiaee2, Shahram Rabbani2, Ali Ghiasedin4, Hanif Tabesh5 and Nazafarin Kamalzade6
1Department of Cardiovascular Surgery, Tehran Heart Center (THC), Tehran University of Medical Sciences (TUMS), Tehran, Iran
2Department of Clinical Research, Tehran Heart Center (THC), Tehran University of Medical Sciences (TUMS), Tehran, Iran
3Department of Small Animal Internal Medicine, School of Veterinary Sciences, Islamic Azad University, Garmsar, Iran
4Biotechnology and Biomedical Group, School of Chemical Engineering, Tarbiat Modares University, Tehran, Iran
5School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran
6Department of Anesthesiology, Tehran University of Medical Sciences (TUMS), Tehran, Iran
*Corresponding Author : Seyed Hossein Ahmadi Tafti, M.D, Department of Cardiovascular Surgery, Tehran Heart Center (THC), Tehran University of Medical Sciences (TUMS), Tehran, Iran, Tel: 00989121153540, Email: [email protected]

Received Date: Jul 26, 2015 / Accepted Date: Oct 07, 2015 / Published Date: Oct 15, 2015

Abstract

Aims: Glucagon-like peptide 1 (GLP-1) is one of the new choices in the management of diabetes mellitus because of its glucose regulatory effects. GLP-1 receptors are expressed not only in islet cells, kidney, lung, brain, and gastrointestinal tract, but also in the heart. The cardiac effects of GLP-1 play a major role in the choice to use this treatment, considering the expression of GLP-1 receptors in heart. Degradation by dipeptidyl peptidase-IV (DPPIV) makes GLP-1’s half-life very short. In this study, the cardiac effects of GLP-1 with chitosan-based scaffold as well as the tissue changes after induction of myocardial infarction in canines were evaluated.
Method: Twelve canines of a similar breed and weight were included in this study. They were categorized into three groups: A case group treated with GLP-1 based on a chitosan scaffold, a group given chitosan with normal saline, and a control group given normal saline alone. Every four weeks after induction of infarction, the troponin-I serum level, regional wall motion abnormality (RWMA), angiogenesis, and microscopic and macroscopic tissue changes were analyzed.
Results: Angiogenesis and infarcted area thickness (which is inversely related to the subsequent risk of pseudoaneurysm development) were significantly higher in the case group compared with the other two groups (p value<0.05). Our case group recorded lower scores of RWMA compared with other canines (p value=0.02).
Conclusion: This investigation revealed that the new compound (GLP-1+chitosan) not only lengthens the releasing duration of GLP-1 but also has cardioprotective effects after myocardial infarction.

Keywords: Heart; Myocardial infarction; Glucagon-like peptide 1; Dogs; Diabetes mellitus

Citation: Zeraatian S, Salehiomran A, Aghdam RM, Tafti SHA, Ghiasi SR (2015) Cardiac Effects of Glucagon-Like Peptide 1 with Chitosan-Based Scaffold after Inducing Myocardial Infarction in Dogs. Cardiol Pharmacol 4: 159. Doi: 10.4172/2329-6607.1000159

Copyright: © 2015 Zeraatian S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Recommended Conferences
  • Middle East Heart Congress

    March 18-20, 2019 Dubai, UAE

  • 5th World Heart Congress

    March 27- 28, 2019 Sydney, Australia

  • 2nd Global Cardiology Summit

    May 13-14, 2019 Perth, Australia

  • 31st Annual Cardiologists Conference

    June 17-19, 2019 Rome, Italy

  • European Cardiology Congress

    July 01-02, 2019 Prague, Czech Republic

  • 6th Global Experts Meeting on Cardiovascular Pharmacology

    July 12-13, 2019 Yokohama, Japan

  • 27th International Conference & Exhibition on Cardiology and Cardiovascular Medicine

    July 26-27, 2019 Kyoto, Japan

  • 27th International Congress on Cardiology and medical interventions

    July 31-August 01, 2019 Chicago, USA

  • 5th World Congress on Cardiology and Cardiovascular Therapeutics

    August 12-13, 2019 Tokyo, Japan

  • 7th World Heart Congress

    August 19- 20, 2019 Vienna, Austria

  • European Heart Congress

    October 23-24, 2019 Amsterdam, Netherlands

  • 32nd European Cardiology Conference

    October 24-26, 2019 Zurich, Switzerland

Article Usage
  • Total views: 13981
  • [From(publication date): 10-2015 - Feb 21, 2019]
  • Breakdown by view type
  • HTML page views: 10129
  • PDF downloads: 3852
Leave Your Message 24x7
Top